Should insulin-sensitizing drugs be used in the treatment of polycystic ovary syndrome?

Reproductive BioMedicine Online

Volumn 8, Issue 4, 2004, Pages 440-447

  Cheang, Kai I ^a   Nestler, John E ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Insulin resistance; Metformin; Thiazolidinediones

Indexed keywords

CLOMIFENE; GONADOTROPIN; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE;

ANOVULATION; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHONDRODYSPLASIA; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG USE; FEMALE; FEMALE INFERTILITY; FETUS DISEASE; FETUS MALFORMATION; FETUS WASTAGE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LACTIC ACIDOSIS; LIVER TOXICITY; METABOLIC SYNDROME X; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; SIDE EFFECT; TERATOGENICITY; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 1842678279     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)60928-5     Document Type: Article

References (58)

1. Adashi EY, Hsueh AJ, Yen SS 1981 Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108, 1441-1449.
2. Azziz R, Ehrmann D, Legro RS et al. 2001 Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 86, 1626-1632.
3. Baillargeon JP, Jakubowicz DJ, Iuorno MJ et al. 2002 Effects of metformin and rosiglitazone, alone and in combination, in lean women with polycystic ovary syndrome and normal indices of insulin sensitivity. The Endocrine Society 84th Annual Meeting, OR10-1.
4. Balen AH, Tan SL, MacDougall J et al. 1993 Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Human Reproduction 8, 959-964.
5. Ben-Shlomo I 2003 The polycystic ovary syndrome: what does insulin resistance have to do with it? Reproductive BioMedicine Online 6, 36-42.
6. Berga SL, Guzick DS, Winters SJ 1993 Increased luteinizing hormone and alpha-subunit secretion in women with hyperandrogenic anovulation. Journal of Clinical Endocrinology and Metabolism 77, 895-901.
7. Bolton AE, Pockley AG, Clough KJ et al. 1987 Identification of placental protein 14 as an immunosuppressive factor in human reproduction. Lancet 1, 593-595.
8. Brown JB, Pedula K, Barzilay J et al. 1998 Lactic acidosis rates in type 2 diabetes. Diabetes Care 21, 1659-1663.
9. Campbell PJ, Gerich JE 1990 Impact of obesity on insulin action in volunteers with normal glucose tolerance: demonstration of a threshold for the adverse effect of obesity. Journal of Clinical Endocrinology and Metabolism 70, 1114-1118.
10. Cibula D, Skrha J, Hill M et al. 2002 Prediction of insulin sensitivity in nonobese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87, 5821-5825.
11. Dalton CF, Laird SM, Serle E et al. 1995 The measurement of CA 125 and placental protein 14 in uterine flushings in women with recurrent miscarriage; relation to endometrial morphology. Human Reproduction 10, 2680-2684.
12. Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New England Journal of Medicine 346, 393-403.
13. Diamanti-Kandarakis E, Baillargeon JP, Iuorno MJ et al. 2003 A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills. Journal of Clinical Endocrinology and Metabolism 88, 1927-1932.
14. Ducluzeau PH, Cousin P, Malvoisin E et al. 2003 Glucose-to-insulin ratio rather than sex hormone-binding globulin and adiponectin levels is the best predictor of insulin resistance in nonobese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 88, 3626-3631.
15. Dunaif A, Segal KR, Futterweit W et al. 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38, 1165-1174.
16. El-Biely MM, Habba M 2001 The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertility Society Journal 6, 43-49.
17. Fleming R, Hopkinson ZE, Wallace AM et al. 2002 Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 87, 569-574.
18. Giudice LC, Mark SP, Irwin JC 1998 Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface. Journal Reproductive Immunology 39, 133-148.
19. Glueck CJ, Wang P, Kobayashi S et al. 2002 Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertility and Sterility 77, 520-525.
20. Hague WM, Davoren PM, Oliver J et al. 2003 Metformin may be useful in gestational diabetes. British Medical Journal 326, 762a.
21. Hellmuth E, Damm P, Molsted-Pedersen L 2000 Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabetic Medicine 17, 507-511.
22. Homburg R, Armar NA, Eshel A et al. 1988 Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. British Medical Journal 297, 1024-1026.
23. Jakubowicz DJ, Seppala M, Jakubowicz S et al. 2001 Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 86, 1126-1133.
24. Jakubowicz DJ, Iuorno MJ, Jakubowicz S et al. 2002 Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 87, 524-529.
25. Jakubowicz DJ, Essah PA, Seppala M et al. 2004 Reduced serum glycodelin and insulin-like growth factor-binding protein-1 in women with polycystic ovary syndrome during first trimester of pregnancy. Journal of Clinical Endocrinology and Metabolism 89, 833-839.
26. Jayagopal V, Kilpatrick ES, Jennings PE et al. 2003 The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycystic ovarian syndrome: implications for SHBG as a surrogate marker of insulin resistance. Journal of Clinical Endocrinology and Metabolism 88, 1528-1533.
27. Jones GC, Macklin JP, Alexander WD 2003 Contraindications to the use of metformin. British Medical Journal 326, 4-5.
28. Jones JI, Gockerman A, Busby WH, Jr et al. 1993 Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α5β1 integrin by means of its Arg-Gly-Asp sequence. Proceedings of the National Academy of Sciences of the USA 90, 10553-10557.
29. Julkunen M, Koistinen R, Sjoberg J et al. 1986 Secretory endometrium synthesizes placental protein 14. Endocrinology 118, 1782-1786.
30. Julkunen M, Koistinen R, Suikkari AM et al. 1990 Identification by hybridization histochemistry of human endometrial cells expressing mRNAs encoding a uterine beta-lactoglobulin homologue and insulin-like growth factor-binding protein-1. Molecular Endocrinology 4, 700-707.
31. Kocak M, Caliskan E, Simsir C et al. 2002 Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome. Fertility and Sterility 77, 101-106.
32. Legro RS, Finegood D, Dunaif A 1998 A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 83, 2694-2698.
33. Lobo RA, Gysler M, March CM et al. 1982 Clinical and laboratory predictors of clomiphene response. Fertility and Sterility 37, 168-174.
34. Lord JM, Flight IHK, Norman RJ 2003 Metformin in polycystic ovary syndrome: systematic review and meta-analysis. British Medical Journal 327, 951-953.
35. Malkawi HY, Qublan HS 2002 The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Medical Journal 23, 663-666.
36. Moghetti P, Castello R, Negri C et al. 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. Journal of Clinical Endocrinology and Metabolism 85, 139-146.
37. Morales AJ, Laughlin GA, Butzow T et al. 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. Journal of Clinical Endocrinology and Metabolism 81, 2854-2864.
38. Nestler JE, Jakubowicz DJ 1996 Decreases in ovarian cytochrome P450c 17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. New England Journal of Medicine 335, 617-623.
39. Nestler JE, Jakubowicz DJ 1997 Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c 17α activity and serum androgens. Journal of Clinical Endocrinology, and Metabolism 82, 4075-4079.
40. Nestler JE, Barlascini CO, Matt DW et al. 1989 Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 68, 1027-1032.
41. Nestler JE, Singh R, Matt DW et al. 1990 Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women. American Journal of Obstetrics and Gynecology 163, 1243-1246.
42. Nestler JE, Powers LP, Matt DW et al. 1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 72, 83-89.
43. Nestler JE, Jakubowicz DJ, Falcon de Vargasm A et al. 1998a Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. Journal of Clinical Endocrinology and Metabolism 83, 2001-2005.
44. Nestler JE, Jakubowicz DJ, Evans WS et al. 1998b Effects of metformin on spontaneous and clomiphene-Induced ovulation in the polycystic ovary syndrome. New England Journal of Medicine 338, 1876-1880.
45. Ng EHY, Wat NMS, Ho PC 2001 Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial. Human Reproduction 16, 1625-1631.
46. Okamoto N, Uchida A, Takakura K et al. 1991 Suppression by human placental protein 14 of natural killer cell activity. American Journal of Reproductive Immunology 26, 137-142.
47. Pasquali R, Gambineri A, Biscotti D et al. 2000 Effect of long-term treatment with metformin added to hypocalloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 85, 2767-2774.
48. Regan L, Owen EJ, Jacobs HS 1990 Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet 336, 1141-1144.
49. Sagle M, Bishop K, Ridley N et al. 1988 Recurrent early miscarriage and polycystic ovaries. British Medical Journal 297, 1027-1028.
50. Seppala M, Riittinen L, Julkunen M et al. 1998 Structural studies, localization in tissue and clinical aspects of human endometrial proteins. Journal of Reproduction and Fertility 36 (suppl.), 127-141.
51. Shepard MK, Balmaceda JP, Leija CG 1979 Relationship of weight to successful induction of ovulation with clomiphene citrate. Fertility and Sterility 32, 641-645.
52. Sturrock ND, Lannon B, Fay TN 2002 Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. British Journal of Clinical Pharmacology 53, 469-473.
53. Suikkari AM, Ruutiainen K, Erkkola R et al. 1989 Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease. Human Reproduction 4, 136-139.
54. Tulppala M, Julkunen M, Tiitinen A et al. 1995 Habitual abortion is accompanied by low serum levels of placental protein 14 in the luteal phase of the fertile cycle. Fertility and Sterility 63, 792-795.
55. UK Prospective Diabetes Study (UKPDS) Group 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352, 854-865.
56. Vandermolen DT, Ratts VS, Evans WS et al. 2001 Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertility and Sterility 75, 310-315.
57. Watson H, Kiddy DS, Hamilton-Fairley D et al. 1993 Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Human Reproduction 8, 829-833.
58. Yarali H, Yildiz BO, Demirol A et al. 2002 Co-administration of metformin during rFSH treatment in patients with clomiphene citrate-resistant polycystic ovarian syndrome: a prospective randomized trial. Human Reproduction 17, 289-294.